CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS - USD ($) shares in Thousands, $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2019	Sep. 30, 2018	Sep. 30, 2019	Sep. 30, 2018
Total revenues	$ 0	$ 0	$ 0	$ 868
Costs and Expenses:
Costs of goods sold	0	0	0	47
Research and development	68,958	38,239	180,053	94,685
Sales and marketing	5,933	5,799	20,160	11,204
General and administrative	11,880	13,131	33,374	42,124
Total costs and expenses	86,771	57,169	233,587	148,060
Operating loss	(86,771)	(57,169)	(233,587)	(147,192)
Changes in fair market value of warrant liabilities	0	1,218	0	(47,808)
Interest expense	(9,747)	(10,142)	(30,331)	(30,476)
Interest and other income	2,195	1,694	6,238	6,389
Insurance reimbursement	0	190	0	2,462
Foreign currency transaction loss, net	0	0	0	(26)
Loss before income tax	(94,323)	(64,209)	(257,680)	(216,651)
Income tax expense	0	0	0	(156)
Net loss	(94,323)	(64,209)	(257,680)	(216,807)
Net loss attributable to noncontrolling interest	(31)	(40)	(98)	(63)
Net loss attributable to Immunomedics, Inc. stockholders	$ (94,292)	$ (64,169)	$ (257,582)	$ (216,744)
Loss per common share attributable to Immunomedics, Inc. stockholders (basic and diluted) (in usd per share)	$ (0.49)	$ (0.34)	$ (1.34)	$ (1.24)
Weighted average shares used to calculated loss per common share (basic and diluted) (in shares)	191,981	186,937	191,596	174,752
Other comprehensive (loss) income, net of tax:
Foreign currency translation adjustments	$ (45)	$ 4	$ 141	$ (12)
Unrealized (loss) gain on securities available for sale	(191)	15	(391)	79
Other comprehensive (loss) income, net of tax:	(236)	19	(250)	67
Comprehensive loss	(94,559)	(64,190)	(257,930)	(216,740)
Comprehensive loss attributable to noncontrolling interest	(31)	(40)	(98)	(63)
Comprehensive loss attributable to Immunomedics, Inc. stockholders	(94,528)	(64,150)	(257,832)	(216,677)
Product sales
Total revenues	0	0	0	450
License fee and other revenues
Total revenues	0	0	0	265
Research and development
Total revenues	$ 0	$ 0	$ 0	$ 153